| Primary |
| Acute Myeloid Leukaemia |
70.5% |
| Myelodysplastic Syndrome |
13.1% |
| Acute Leukaemia |
2.7% |
| Prophylaxis |
1.9% |
| Pyrexia |
1.5% |
| Febrile Neutropenia |
1.1% |
| Hypertension |
1.1% |
| Bone Pain |
1.0% |
| Chemotherapy |
0.9% |
| Acute Myeloid Leukaemia Recurrent |
0.8% |
| Infection Prophylaxis |
0.8% |
| Leukaemia |
0.8% |
| Leukaemia Recurrent |
0.8% |
| Drug Use For Unknown Indication |
0.5% |
| Infection |
0.5% |
| Myeloid Leukaemia |
0.5% |
| Pain |
0.5% |
| Antiemetic Supportive Care |
0.4% |
| Neutropenia |
0.4% |
| Acute Myeloid Leukemia |
0.3% |
|
| Sepsis |
15.2% |
| Neutropenic Sepsis |
9.8% |
| Venoocclusive Liver Disease |
8.8% |
| Thrombocytopenia |
8.1% |
| Pneumonia |
7.7% |
| Septic Shock |
5.7% |
| Disease Progression |
5.4% |
| Respiratory Failure |
5.1% |
| Renal Failure |
4.4% |
| Multi-organ Failure |
3.7% |
| Myocardial Infarction |
3.4% |
| Neutropenia |
3.0% |
| Tachypnoea |
3.0% |
| Lung Infection |
2.7% |
| Gamma-glutamyltransferase Increased |
2.4% |
| Hepatotoxicity |
2.4% |
| Pulmonary Haemorrhage |
2.4% |
| Respiratory Distress |
2.4% |
| Tumour Lysis Syndrome |
2.4% |
| Vomiting |
2.4% |
|
| Secondary |
| Acute Myeloid Leukaemia |
51.7% |
| Myelodysplastic Syndrome |
22.8% |
| Product Used For Unknown Indication |
8.1% |
| Prophylaxis |
2.6% |
| Bone Pain |
1.9% |
| Cord Blood Transplant Therapy |
1.9% |
| Acute Promyelocytic Leukaemia |
1.6% |
| Prophylaxis Against Graft Versus Host Disease |
1.3% |
| Leukaemia Recurrent |
1.2% |
| Pyrexia |
1.1% |
| Premedication |
1.0% |
| Acute Myeloid Leukemia |
0.8% |
| Drug Use For Unknown Indication |
0.7% |
| Acute Leukaemia |
0.6% |
| Sepsis |
0.5% |
| Acute Monocytic Leukaemia |
0.5% |
| Antifungal Treatment |
0.5% |
| Full Blood Count Decreased |
0.5% |
| Acute Biphenotypic Leukaemia |
0.4% |
| Acute Myeloid Leukemia Nos |
0.4% |
|
| Sepsis |
11.9% |
| Thrombocytopenia |
10.9% |
| Venoocclusive Liver Disease |
10.4% |
| Platelet Count Increased |
7.8% |
| Infusion Related Reaction |
5.7% |
| Respiratory Failure |
5.7% |
| Alanine Aminotransferase Increased |
4.1% |
| Convulsion |
4.1% |
| Neutropenia |
4.1% |
| Febrile Neutropenia |
3.6% |
| Gamma-glutamyltransferase Increased |
3.6% |
| Respiratory Distress |
3.6% |
| Bronchopulmonary Aspergillosis |
3.1% |
| Liver Disorder |
3.1% |
| Neutropenic Sepsis |
3.1% |
| Pancreatitis Acute |
3.1% |
| Renal Failure |
3.1% |
| Sinus Tachycardia |
3.1% |
| Vaginal Haemorrhage |
3.1% |
| Cardiac Arrest |
2.6% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
18.4% |
| Cord Blood Transplant Therapy |
14.3% |
| Prophylaxis Against Graft Versus Host Disease |
10.2% |
| Prophylaxis |
9.5% |
| Antifungal Prophylaxis |
5.6% |
| Bone Marrow Conditioning Regimen |
4.5% |
| Insomnia |
4.0% |
| Liver Abscess |
4.0% |
| Premedication |
3.6% |
| Graft Versus Host Disease |
3.3% |
| Allergy Prophylaxis |
3.2% |
| Antibiotic Prophylaxis |
2.8% |
| Neutropenia |
2.8% |
| Acute Monocytic Leukaemia |
2.6% |
| Product Used For Unknown Indication |
2.5% |
| Febrile Neutropenia |
2.0% |
| Acute Myeloid Leukaemia Recurrent |
1.9% |
| Stem Cell Transplant |
1.7% |
| Antiviral Prophylaxis |
1.6% |
| Constipation Prophylaxis |
1.6% |
|
| Venoocclusive Liver Disease |
11.9% |
| Weight Increased |
11.9% |
| Drug Ineffective |
10.2% |
| White Blood Cell Count Decreased |
10.2% |
| Platelet Count Decreased |
6.8% |
| Respiratory Failure |
6.8% |
| Blast Cells Present |
5.1% |
| Petechiae |
5.1% |
| Acute Myeloid Leukaemia Recurrent |
3.4% |
| Cardiac Failure |
3.4% |
| Cranial Nerve Disorder |
3.4% |
| Disseminated Intravascular Coagulation |
3.4% |
| Gastric Antral Vascular Ectasia |
3.4% |
| Off Label Use |
3.4% |
| Prothrombin Time Prolonged |
3.4% |
| Asthenia |
1.7% |
| Cholecystitis |
1.7% |
| Colitis |
1.7% |
| Diarrhoea |
1.7% |
| Fatigue |
1.7% |
|
